Pioglitazone after Ischemic Stroke or Transient Ischemic Attack

Cited by (1,110)

Items 201–300 of 1,110

1. Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus
   Young, Lawrence H., Viscoli, Catherine M., Curtis, Jeptha P., Inzucchi, Silvio E., Schwartz, Gregory G., Lovejoy, Anne M., Furie, Karen L., Gorman, Mark J., Conwit, Robin, Abbott, J. Dawn et al. · 2017 · Circulation
2. Necrostatin-1 Improves Long-term Functional Recovery Through Protecting Oligodendrocyte Precursor Cells After Transient Focal Cerebral Ischemia in Mice
   Yingzhu Chen, Lingling Zhang, Hailong Yu, Kangping Song, Jinling Shi, Linlin Chen, Jian Gong Cheng · 2017 · Neuroscience
3. Prevention of cardiorenal complications in people with type 2 diabetes and obesity
   Daniel J. Drucker · 2024 · Cell Metabolism
4. Consensus recommendations for management of patients with type 2 diabetes mellitus and cardiovascular diseases
   Alaaeldin M. Bashier, Azza Khalifa Bin Hussain, Elamin Abdelgadir, Fatheya Alawadi, Hani Mohamed Sabbour, ROBERT J. CHILTON · 2019 · Diabetology & Metabolic Syndrome
5. Pioglitazone Prevents Stroke in Patients With a Recent Transient Ischemic Attack or Ischemic Stroke
   Shadi R. Yaghi, Karen L. Furie, Catherine M. Viscoli, Hooman Kamel, Mark Gorman, Jennifer L. Dearborn, Lawrence H. Young, Silvio E. Inzucchi, Anne M. Lovejoy, Scott Eric Kasner et al. · 2017 · Circulation
6. LRP1 Deficiency in Vascular SMC Leads to Pulmonary Arterial Hypertension That Is Reversed by PPARγ Activation
   Laurent Calvier, Philippe Boucher, Joachim Herz · 2019 · Circulation Research
7. Triglyceride/High‐Density Lipoprotein Cholesterol Ratio: A Clue to Metabolic Syndrome, Insulin Resistance, and Severe Atherosclerosis
   Mahmoud Reza Azarpazhooh, Farid Najafi, Mitra Darbandi, Soushyant Kiarasi, Temilola Oduyemi, John David Spence · 2021 · Lipids
8. Type 2 Diabetes Mellitus and Impaired Renal Function Are Associated With Brain Alterations and Poststroke Cognitive Decline
   Einor Ben Assayag, Roy Eldor, Amos D. Korczyn, Efrat Kliper, Shani Shenhar‐Tsarfaty, Oren Tene, Jeremy Molad, Itzhak Shapira, Shlomo A. Berliner, Viki Volfson et al. · 2017 · Stroke
9. Legacy effect of intensive glucose control on major adverse cardiovascular outcome: Systematic review and meta-analyses of trials according to different scenarios
   Francesco Prattichizzo, Paola de Candia, Valeria De Nigris, Antonio Nicolucci, Antonio Ceriello · 2020 · Metabolism
10. DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases
    Handelsman, Yehuda, Anderson, John E., Bakris, George L., Ballantyne, Christie M., Beckman, Joshua A., Bhatt, Deepak L., Bloomgarden, Zachary T., Bozkurt, Biykem, Budoff, Matthew J., Butler, Javed et al. · 2022 · Journal of Diabetes and its Complications
11. Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm
    Muhammad A. Abdul-Ghani, Ralph Anthony DeFronzo · 2017 · Diabetes Care
12. Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes
    Clarke, Geoffrey D., Solis-Herrera, Carolina, Molina-Wilkins, Marjorie, Martinez, Sandra, Merovci, Aurora, Cersosimo, Eugenio, Chilton, Robert J., Iozzo, Patricia, Gastaldelli, Amalia, Abdul-Ghani, Muhammad et al. · 2017 · Diabetes Care
13. Artesunate suppresses oxidative and inflammatory processes by activating Nrf2 and ROS‑dependent p38 MAPK and protects against cerebral ischemia‑reperfusion injury
    Hui Lu, Bincheng Wang, Ningning Cui, Yanchun Zhang · 2018 · Molecular Medicine Reports
14. An Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes
    Rosaria Vincenza Giglio, Νικόλαος Παπάνας, Ali Abbas Rizvi, Marcello Ciaccio, Angelo Maria Patti, Ιoannis Ilias, Anca Pantea Stoian, Amirhossein Sahebkar, Andrej Janež, Manfredi Rizzo · 2022 · Medicina
15. Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes
    Eberhard Standl, Oliver Schnell, Darren K. McGuire · 2016 · Circulation Research
16. Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms
    Bart Staels · 2017 · The American Journal of Cardiology
17. PPARγ deacetylation dissociates thiazolidinedione’s metabolic benefits from its adverse effects
    Michael James Kraakman, Qiongming Liu, Jorge Postigo-Fernandez, Ruiping Ji, Ning Kon, Delfina Larrea, Maria Namwanje, Lihong Fan, Michelle Chan, Estela Área-Gómez et al. · 2018 · Journal of Clinical Investigation
18. Targeting perivascular and epicardial adipose tissue inflammation: therapeutic opportunities for cardiovascular disease
    Rim W. Rafeh, Anissa Viveiros, Gavin Y. Oudit, Ahmed Fawzy EL‐Yazbi · 2020 · Clinical Science
19. Obesity, diabetes mellitus, and cardiometabolic risk: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2023
    Harold Edward Bays, Shagun Bindlish, Tiffany Lowe Clayton · 2023 · Obesity Pillars
20. Prevention of Diabetes Mellitus in Patients With Prediabetes
    Nicholas W. Carris, Ronald R. Magness, Arthur J. Labovitz · 2018 · The American Journal of Cardiology
21. Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease
    Jeffrey Thomas Budd, Kenneth J. Cusi · 2020 · Current Diabetes Reports
22. Neuroanesthesiology Update
    Jeffrey J. Pasternak, William L. Lanier · 2009 · Journal of Neurosurgical Anesthesiology
23. Recent Advances in the Treatment of Insulin Resistance Targeting Molecular and Metabolic Pathways: Fighting a Losing Battle?
    Marta Wołosowicz, Sławomir Prokopiuk, Tomasz Waldemar Kaminski · 2022 · Medicina
24. Experimental ischaemic stroke induces transient cardiac atrophy and dysfunction
    Roland C. Veltkamp, Stefan Uhlmann, Marilena Marinescu, Carsten Sticht, Daniel Finke, Norbert Gretz, Herrmann‐Josef Gröne, Hugo Albert Katus, Johannes Backs, Lorenz Lehmann · 2018 · Journal of Cachexia Sarcopenia and Muscle
25. Dietary and pharmacological treatment in patients with metabolic-dysfunction associated steatotic liver disease
    Angelo Armandi, Elisabetta Bugianesi · 2024 · European Journal of Internal Medicine
26. Nuclear receptors in podocyte biology and glomerular disease
    Shipra Agrawal, Cijiang He, Pierre‐Louis Tharaux · 2020 · Nature Reviews Nephrology
27. Debate on Insulin vs Non-insulin Use in the Hospital Setting—Is It Time to Revise the Guidelines for the Management of Inpatient Diabetes?
    Francisco J. Pasquel, Maya Fayfman, Guillermo E. Umpierrez · 2019 · Current Diabetes Reports
28. Insulin resistance is associated with poor functional outcome after acute ischemic stroke in non-diabetic patients
    Yoonkyung Chang, Chi Kyung Kim, Minkyung Kim, Woo‐Keun Seo, Kyungmi Oh · 2021 · Scientific Reports
29. Pathogenesis, Clinical Features and Treatment of Diabetic Cardiomyopathy
    Núria Alonso, Pedro Moliner, Dídac Mauricio · 2017 · Advances in experimental medicine and biology
30. PPARγ is a gatekeeper for extracellular matrix and vascular cell homeostasis
    Gábor Kökény, Laurent Calvier, Ekaterina Legchenko, Philippe Chouvarine, Miklos M Mozes, Georg Hansmann · 2019 · Current Opinion in Nephrology & Hypertension
31. Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes
    Maryam Khavandi, Francisco Duarte, Henry N. Ginsberg, Gissette Reyes‐Soffer · 2017 · Current Cardiology Reports
32. Effect of glucose-lowering therapies on heart failure
    Michael E. Nassif, Mikhail Kosiborod · 2018 · Nature Reviews Cardiology
33. Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials
    Clifford J. Bailey, Nikolaus Marx · 2018 · Diabetes Obesity and Metabolism
34. Association of the triglyceride–glucose index with coronary artery disease complexity in patients with acute coronary syndrome
    Shiqiang Xiong, Qiang Chen, Long Yu, Hong Su, Yan Luo, Hanxiong Liu, Yingzhong Chen, Qiao Feng, Xiufen Peng, Maoling Jiang et al. · 2023 · Cardiovascular Diabetology
35. Revitalization of pioglitazone: the optimum agent to be combined with a sodium‐glucose co‐transporter‐2 inhibitor
    R. A. DeFronzo, ROBERT J. CHILTON, Luke Norton, G. Clarke, Robert E. J. Ryder, Muhammad A Abdul‐Ghani · 2016 · Diabetes Obesity and Metabolism
36. The application of lag times in cancer pharmacoepidemiology: a narrative review
    Blanaid M. Hicks, James A. Kaye, Laurent Azoulay, Kasper Bruun Kristensen, Laurel A. Habel, Anton Pottegård · 2023 · Annals of Epidemiology
37. Diabetes, stroke, and neuroresilience: looking beyond hyperglycemia
    Matthew J. Krinock, Neel S. Singhal · 2021 · Annals of the New York Academy of Sciences
38. Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes
    André Jacques Scheen · 2018 · Diabetes & Metabolism
39. Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone
    Lawrence H. Young, Catherine M. Viscoli, Gregory G. Schwartz, Silvio E. Inzucchi, Jeptha P. Curtis, Mark Gorman, Karen L. Furie, ROBIN A. CONWIT, Erica Sarah Spatz, Anne M. Lovejoy et al. · 2018 · Circulation
40. A Precision Medicine Approach to Cerebral Edema and Intracranial Hypertension after Severe Traumatic Brain Injury: Quo Vadis?
    Ruchira Menka Jha, Patrick Michael Kochanek · 2018 · Current Neurology and Neuroscience Reports
41. Assessment of Nonfatal Myocardial Infarction as a Surrogate for All-Cause and Cardiovascular Mortality in Treatment or Prevention of Coronary Artery Disease
    Kevin O’Fee, Elena Deych, Oriana Ciani, David Brown · 2021 · JAMA Internal Medicine
42. Response to pioglitazone in non-alcoholic fatty liver disease patients with vs. without type 2 diabetes: A meta-analysis of randomized controlled trials
    Zeyu Wang, Du Huiqing, Ying Zhao, Yadi Ren, Cuihua Ma, Hongyu Chen, Man Li, Jiageng Tian, Caihong Xue, Guangfeng Long et al. · 2023 · Frontiers in Endocrinology
43. MASLD/MASH and type 2 diabetes: Two sides of the same coin? From single PPAR to pan-PPAR agonists
    Michael P. Cooreman, Luisa Vonghia, Sven Francque · 2024 · Diabetes Research and Clinical Practice
44. Interdisciplinary perspectives on the co-management of metabolic dysfunction-associated steatotic liver disease and coronary artery disease
    Jacob J. Gries, Jeffrey Victor Lazarus, Paul Brennan, Mohammad Shadab Siddiqui, Giovanni Targher, Chim Choy Lang, Salim S. Virani, Carl J. Lavie, Scott D. Isaacs, Juan Pablo Arab et al. · 2024 · The Lancet. Gastroenterology & hepatology
45. Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational study
    Cheng-Wei Chan, Chu-Leng Yu, Jiunn‐Cherng Lin, Yu‐Cheng Hsieh, Che‐Chen Lin, Chen-Ying Hung, Cheng-Hung Li, Ying‐Chieh Liao, Chu‐Pin Lo, Jin‐Long Huang et al. · 2018 · Cardiovascular Diabetology
46. Association between Body Fat and Diabetic Peripheral Neuropathy in Middle-Aged Adults with Type 2 Diabetes Mellitus: A Preliminary Report
    Tae Jung Oh, Jie-Eun Lee, Sung Hee Choi, Hak Chul Jang · 2019 · Journal of Obesity & Metabolic Syndrome
47. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus
    Yandrapalli, Srikanth, Jolly, George, Horblitt, Adam, Sanaani, Abdallah, Aronow, Wilbert S. · 2017 · Postgraduate Medicine
48. Study on insulin resistance and ischemic cerebrovascular disease: A bibliometric analysis via CiteSpace
    Xue Zhou, Kang Chen, YuHong Hu, XingChen Wang · 2023 · Frontiers in Public Health
49. Antidiabetic drugs and stroke risk. Current evidence
    Luis Castilla‐Guerra, María del Carmen Fernández‐Moreno, David León Jiménez, Eduardo Carmona Nimo · 2017 · European Journal of Internal Medicine
50. Clusterin and Its Role in Insulin Resistance and the Cardiometabolic Syndrome
    Jennifer A. Wittwer, David P. Bradley · 2021 · Frontiers in Immunology
51. Should Side Effects Influence the Selection of Antidiabetic Therapies in Type 2 Diabetes?
    George Grunberger · 2017 · Current Diabetes Reports
52. Inflammation and adiposity: new frontiers in atrial fibrillation
    Vishal S. Vyas, Ross Jacob Hunter, Maria Paula Longhi, Malcolm Finlay · 2020 · EP Europace
53. Association of triglyceride-glucose index with clinical outcomes in patients with acute ischemic stroke receiving intravenous thrombolysis
    Emma Min Shuen Toh, Amanda Yuan Ling Lim, Chua Ming, Leonard L.L. Yeo, Ching‐Hui Sia, Bryce Wei Quan Tan, Aloysius Sheng‐Ting Leow, Jamie Sin Ying Ho, Bernard Chan, Vijay Kumar Sharma et al. · 2022 · Scientific Reports
54. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
    Kejia Hu, Wendong Xu, Ziv M. Williams · 2016 · New England Journal of Medicine
55. Pharmacological Utility of PPAR Modulation for Angiogenesis in Cardiovascular Disease
    Nicole Wagner, Kay‐Dietrich Wagner · 2023 · International Journal of Molecular Sciences
56. Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: A population‐based cohort study
    Kristian B. Filion, Antonios Douros, Laurent Azoulay, Hui Yin, Oriana Hoi Yun Yu, Samy Suissa · 2019 · British Journal of Clinical Pharmacology
57. Cardiovascular safety of glucose‐lowering agents as add‐on medication to metformin treatment in type 2 diabetes: report from the S wedish N ational D iabetes R egister
    Nils Ekström, Ann‐Marie Svensson, Mervete Miftaraj, Stefan Franzén, Björn Zethelius, Björn Eliasson, Soffia Guðbjörnsdóttir · 2016 · Diabetes Obesity and Metabolism
58. Insulin Resistance Is a Risk Factor for Silent Lacunar Infarction
    Ji Eun Lee, Dong Wook Shin, Jae Moon Yun, Sang Hyuck Kim, You‐Seon Nam, Belong Cho, Jae‐Sung Lim, Han‐Yeong Jeong, Hyung‐Min Kwon, Jin‐Ho Park · 2016 · Stroke
59. Pioglitazone Reduces Dementia Risk in Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Analysis
    Chin‐Hsiao Tseng · 2018 · Journal of Clinical Medicine
60. The Atherogenic Index of Plasma is Independently Associated with Symptomatic Carotid Artery Stenosis
    Ravi Garg, Natalie Knox, Supritha Prasad, Shuchi Zinzuwadia, Megan A. Rech · 2020 · Journal of Stroke and Cerebrovascular Diseases
61. Assessing the need for pioglitazone in the treatment of patients with type 2 diabetes: A meta-analysis of its risks and benefits from prospective trials
    Sinha, Binayak, Ghosal, Samit · 2020 · Scientific Reports
62. Relation between HOMA-IR and insulin sensitivity index determined by hyperinsulinemic-euglycemic clamp analysis during treatment with a sodium-glucose cotransporter 2 inhibitor
    So, Anna, Sakaguchi, Kazuhiko, Okada, Yuko, Morita, Yasuko, Yamada, Tomoko, Miura, Hiroshi, Otowa-Suematsu, Natsu, Nakamura, Tomoaki, Komada, Hisako, Hirota, Yushi et al. · 2020 · Endocrine Journal
63. Pioglitazone improves whole‐body aerobic capacity and skeletal muscle energy metabolism in patients with metabolic syndrome
    Takashi Yokota, Shintaro Kinugawa, Kagami Hirabayashi, Tadashi Suga, Shingo Takada, Masashi Omokawa, Tomoyasu Kadoguchi, Masashige Takahashi, Arata Fukushima, Shouji Matsushima et al. · 2016 · Journal of Diabetes Investigation
64. Nondiabetic Glucometabolic Status and Progression of Aortic Stiffness: The Whitehall II Study
    Carmel M. McEniery, Ian B. Wilkinson, Nanna Borup Johansen, Daniel R. Witte, Archana Singh‐Manoux, Mika Kivimaki B, Ádám Gyula Tabák, Eric John Brunner, Martin J. Shipley · 2017 · Diabetes Care
65. Efficacy and safety of thiazolidinediones in diabetes patients with renal impairment: a systematic review and meta-analysis
    Wen Wang, Xu Zhou, Joey SW Kwong, Ling Li, Youping Li, Xin Sun · 2017 · Scientific Reports
66. Prediabetes and Outcome of Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-analysis
    Yuesong Pan, Weiqi Chen, Yongjun Wang · 2018 · Journal of Stroke and Cerebrovascular Diseases
67. The future of new drugs for diabetes management
    Clifford J. Bailey, Caroline Day · 2019 · Diabetes Research and Clinical Practice
68. Diabetes drugs and stroke risk: Intensive versus conventional glucose‐lowering strategies, and implications of recent cardiovascular outcome trials
    Soo Kyung Lim, Tae Jung Oh, Jesse Dawson, Naveed A. Sattar · 2019 · Diabetes Obesity and Metabolism
69. Prediabetes and risk of diabetes and associated complications
    Muhammad A Abdul‐Ghani, Ralph A. DeFronzo, Amin Jayyousi · 2016 · Current Opinion in Clinical Nutrition & Metabolic Care
70. Inflammation and the Silent Sequelae of Stroke
    Kyra J. Becker · 2016 · Neurotherapeutics
71. Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable
    Francesco Cosentino, Antonio Ceriello, Florian M.M. Baeres, Paola Fioretto, Alan J. Garber, Wendy Gattis Stough, Jyothis Thomas George, Peter J. Grant, Kamlesh Khunti, Anna Maria Langkilde et al. · 2018 · European Heart Journal
72. Dopamine in the Regulation of Glucose Homeostasis, Pathogenesis of Type 2 Diabetes, and Chronic Conditions of Impaired Dopamine Activity/Metabolism: Implication for Pathophysiological and Therapeutic Purposes
    Giuseppe Lisco, Anna De Tullio, Michele Iovino, Olga Disoteo, Edoardo Guastamacchia, Vito Angelo Giagulli, Vincenzo Triggiani · 2023 · Biomedicines
73. Adipokines in neurovascular diseases
    Radka Opatřilová, Martin Čaprnda, Peter Kubatka, Vanda Valentová, Sona Uramova, Vladimír Nosáľ, Ľudovít Gašpar, Lukáš Zachar, Ioana Monica Mozos, Daniel Petrovič et al. · 2017 · Biomedicine & Pharmacotherapy
74. Echocardiographic feature of diabetic cardiomyopathy: where are we now?
    Kazuaki Negishi · 2018 · Cardiovascular Diagnosis and Therapy
75. Protection against stroke with glucagon‐like peptide 1 receptor agonists: a systematic review and meta‐analysis
    Fotios Barkas, Moses Elisaf, Haralampos J. Milionis · 2019 · European Journal of Neurology
76. RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020
    Rajeev Chawla, S. V. Madhu, B. M. Makkar, Sujoy Kumar Ghosh, Banshi Saboo, Sanjay Kalra, On behalf of RSSDI-ESI Consensus Group · 2020 · International Journal of Diabetes in Developing Countries
77. After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists?
    Bruno L Vergès, Bernard H. Charbonnel · 2017 · Diabetes & Metabolism
78. Cardiovascular disease prevention strategies for type 2 diabetes mellitus
    Niki Katsiki, Francesco Purrello, Costas P. Tsioufis, Dimitri P. Mikhailidis · 2017 · Expert Opinion on Pharmacotherapy
79. Glucose-Lowering Therapies for Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: State-of-the-Art Review
    Salvatore Carbone, Dave L. Dixon, Leo Francis Buckley, Antonio Abbate · 2018 · Mayo Clinic Proceedings
80. Treatment Approaches to Lacunar Stroke
    Alvin S. Das, Robert William Regenhardt, Steven K. Feske, M. Edip Gurol · 2019 · Journal of Stroke and Cerebrovascular Diseases
81. Activation of the Metabolic Master Regulator PPARγ: A Potential PIOneering Therapy for Pulmonary Arterial Hypertension
    Georg Hansmann, Laurent Calvier, Michael G. Risbano, Stephen Y. Chan · 2019 · American Journal of Respiratory Cell and Molecular Biology
82. COVID-19: Diabetes Perspective—Pathophysiology and Management
    Siva Dallavalasa, SubbaRao V. Tulimilli, Prakash Janhavi, Ramya Ramachandra, SubbaRao V. Madhunapantula, Ravindra P. Veeranna · 2023 · Pathogens
83. An explainable machine learning-based phenomapping strategy for adaptive predictive enrichment in randomized clinical trials
    Evangelos K. Oikonomou, Phyllis Thangaraj, Deepak L. Bhatt, Joseph S. Ross, Lawrence H. Young, Harlan M. Krumholz, Marc A. Suchard, Rohan Khera · 2023 · npj Digital Medicine
84. Amelioration of perivascular adipose inflammation reverses vascular dysfunction in a model of nonobese prediabetic metabolic challenge: potential role of antidiabetic drugs
    Mohammed A.W. Elkhatib, Ali Mroueh, Rim W. Rafeh, Fatima Sleiman, Hosny H. Fouad, Evan I. Saad, Mohamed A. Fouda, Ola Elgaddar, Khodr Issa, Ali Hussein Eid et al. · 2019 · Translational research
85. Treatment of dyslipidemia in diabetes: recent advances and remaining questions
    Chait, Alan, Goldberg, Ira · 2017 · Current Diabetes Reports
86. A synergistic effect of the triglyceride-glucose index and the residual SYNTAX score on the prediction of intermediate-term major adverse cardiac events in patients with type 2 diabetes mellitus undergoing percutaneous coronary intervention
    Shiqiang Xiong, Qiang Chen, Zhen Zhang, Yingzhong Chen, Jun Wei Hou, Caiyan Cui, Lian-Chao Cheng, Hong Su, Long Yu, Siqi Yang et al. · 2022 · Cardiovascular Diabetology
87. 3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2026
    Mandeep Singh Bajaj, Rozalina G. McCoy, Kirthikaa Balapattabi, Raveendhara R. Bannuru, Natalie J. Bellini, Allison K. Bennett, Elizabeth Ann Beverly, Kathaleen Briggs Early, Sathyavathi ChallaSivaKanaka, Justin Basile Echouffo-Tcheugui et al. · 2025 · Diabetes Care
88. Emerging roles of sodium–glucose cotransporter 2 inhibitors in cardiology
    Atsushi Tanaka, Koichi Node · 2016 · Journal of Cardiology
89. Is It Time to Change the Type 2 Diabetes Treatment Paradigm? No! Metformin Should Remain the Foundation Therapy for Type 2 Diabetes
    Silvio E. Inzucchi · 2017 · Diabetes Care
90. Unbreakable? An analysis of the fragility of randomized trials that support diabetes treatment guidelines
    B. Chase Kruse, Matt B. Vassar · 2017 · Diabetes Research and Clinical Practice
91. Chronic Kidney Disease-Induced Insulin Resistance: Current State of the Field
    Natasha Dave, Jiao Wu, Sandhya S. Thomas · 2018 · Current Diabetes Reports
92. Neuroprotective effects of MHY908, a PPAR α/γ dual agonist, in a MPTP-induced Parkinson’s disease model
    Yujeong Lee, Jung-Hyun Cho, Seulah Lee, Wonjong Lee, Seung‐Cheol Chang, Hae Young Chung, Hyung Ryong Moon, Jaewon Lee · 2018 · Brain Research
93. Treating Hepatic Steatosis and Fibrosis by Modulating Mitochondrial Pyruvate Metabolism
    McCommis, Kyle S., Finck, Brian N. · 2019 · Cellular and Molecular Gastroenterology and Hepatology
94. The brain penetrant PPARγ agonist leriglitazone restores multiple altered pathways in models of X-linked adrenoleukodystrophy
    Rodríguez-Pascau, Laura, Vilalta, Anna, Cerrada, Marc, Traver, Estefania, Forss-Petter, Sonja, Weinhofer, Isabelle, Bauer, Jan, Kemp, Stephan, Pina, Guillem, Pascual, Sílvia et al. · 2021 · Science Translational Medicine
95. Use of oral diabetes medications and the risk of incident dementia in US veterans aged ≥60 years with type 2 diabetes
    Xin Tang, Roberta Dı́az Brinton, Zhao Chen, Leslie V. Farland, Yann C. Klimentidis, Raymond Q. Migrino, Peter D. Reaven, Kathleen E. Rodgers, Jin J. Zhou · 2022 · BMJ Open Diabetes Research & Care
96. Insulin Resistance and Future Cognitive Performance and Cognitive Decline in Elderly Patients with Cardiovascular Disease
    Miri Lutski, Galit Weinstein, Uri Goldbourt, David Tanné · 2017 · Journal of Alzheimer s Disease
97. Role of diabetes in stroke: Recent advances in pathophysiology and clinical management
    Sian Bradley, Kevin J. Spring, Roy Gary Beran, Dimitrios Chatzis, Murray C. Killingsworth, Sonu M. M. Bhaskar · 2021 · Diabetes/Metabolism Research and Reviews
98. The role of NLRP3 in traumatic brain injury and its regulation by pioglitazone
    Ho Jun Yi, Jung Eun Lee, Dong Hoon Lee, Young Il Kim, Chul Bum Cho, Il Sup Kim, Jae Hoon Sung, Seung Ho Yang · 2019 · Journal of neurosurgery
99. Association of Silent Cerebrovascular Disease Identified Using Natural Language Processing and Future Ischemic Stroke
    David M. Kent, Lester Y. Leung, Yichen Zhou, Patrick H. Luetmer, David F. Kallmes, Jason Nelson, Sunyang Fu, Chengyi Zheng, Hongfang Liu, Wansu Chen · 2021 · Neurology
100. Impact of glucose-lowering therapies on risk of stroke in type 2 diabetes
     Fabrice Bonnet, André Jacques Scheen · 2017 · Diabetes & Metabolism